Update on Colorectal Carcinomatosis—From Molecular Biology to Diagnosis and Management

Sandra F. Martins, Adhemar Longatto Filho

Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.

DOI: 10.4236/ss.2013.45048                

Abstract

After liver metastases, Peritoneal Carcinomatosis (PC) is the second most frequent cause of death in patients with Colorectal Cancer (CRC), although the precise incidence of Colorectal Cancer Peritoneal Carcinomatosis is not known, as the majority of the diagnostic studies cannot detect the disease in its initial stages, nowadays, the diagnosis of peritoneal carcinomatosis remains a challenge. The molecular biology of PC is only just beginning to be understood, future knowledge will permit not only identify novel strategies for PC prevention, but also contribute to therapeutic advances, through the development of molecular targeted therapies. The authors performed a literature revision about the Molecular Biology, Diagnosis and Management of Colorectal Cancer Peritoneal carcinomatosis.

Keywords

Peritoneal Carcinomatosis; Colorectal Cancer; Molecular Biology; Diagnosis; Management

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	V. E. Lemmens, I. H. de Hingh, et al., “Predictors and Survival of Synchronous Peritoneal Carcinomatosis of Colorectal Origin: A Population-Based Study,” International Journal of Cancer, Vol. 128, No. 11, 2011, pp. 2717-2725. doi:10.1002/ijc.25596
[2]	A. Gómez Portilla, I. Cendoya, I. López de Tejada, I. Olabarría, C. M. de Lecea, L. Magrach, A. Gil, J. Echevarría, M. Valdovinos and I. Larrabide, “Peritoneal Carcinomatosis of Colorectal Origin. Current Treatment. Review and Update,” Revista Espa?ola de Enfermedades Digestivas, Vol. 97, No. 10, 2005. doi:10.4321/S1130-01082005001000005
[3]	D. Elias, F. Gilly, F. Boutitie, F. Quenet, J.-M. Bereder, B. Mansvelt, G. Lorimier, P. Dubè and O. Glehen, “Peritoneal Colorectal Carcinomatosis Treated with Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients from a Multicentric French Study,” Journal of Clinical Oncology, Vol. 28, No. 1, 2010, pp. 63-68.
[4]	A. Macrì, E. Saladino, V. Bartolo, V. Adamo, G. Altavilla E. Mondello, G. Condemi, A. Sinardi and C. Famulari, “Peritoneal Carcinomatosis of Colorectal Origin,” World Journal of Gastrointestinal Oncology, Vol. 2, No. 2, 2010, pp. 98-101. doi:10.4251/wjgo.v2.i2.98
[5]	D. Goéré, “Incidence and Prognosis of Synchronous Colorectal Carcinomatosis: Evolution since 1985?” Future Oncology, Vol. 7, No. 11, 2011, pp. 1265-1268.
[6]	D. Jayne, “Molecular Biology of Peritoneal Carcinomatosis. Peritoneal Carcinomatosis: A Multidisciplinary Approach,” Springer, Berlin, 2007, pp. 21-33.
[7]	S. Kusamura, D. Baratti, N. Zaffaroni, R. Villa, B. Laterza, M. R. Balestra, et al., “Pathophysiology and Biology of Peritoneal Carcinomatosis,” World Journal of Gastrointestinal Oncology, Vol. 2, No. 1, 2010, pp. 12-18.
[8]	D. G. Jayne, “The Molecular Biology of Peritoneal Carcinomatosis from Gastrointestinal Cancer,” Annals Academy of Medicine Singapore, Vol. 32, No. 2, 2003, pp. 219-225.
[9]	P. Wim and M. E. B. Ceelen, “Peritoneal Minimal Residual Disease in Colorectal Cancer: Mechanisms, Prevention, and Treatment,” The Lancet Oncology, Vol. 10, No. 1, 2009, pp. 72-79. doi:10.1016/S1470-2045(08)70335-8
[10]	E. M. V. de Cuba, R. Kwakman, M. van Egmond, L. J. W. Bosch, H. J. Bonjer, G. A. Meijer and E. A. te Velde, “Understanding Molecular Mechanisms in Peritoneal Dissemination of Colorectal Cancer: Future Possibilities for Personalised Treatment by Use of Biomarkers,” Virchows Archiv, Vol. 461, No. 3, 2012, pp. 231-243. doi:10.1007/s00428-012-1287-y
[11]	S. Zerhouni and J. A. Mccart, “Peritoneal Carcinomatosis of Colorectal Origin. Is There a Role for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?” Colorectal Disease, Vol. 11, No. 2, 2012, pp. 14-19.
[12]	A. J. Suleiman, N. A. Uraiqat and O. A. Al-Imam, “Peritoneal Carcinomatosis Computerized Tomography Scans Findings and Causes,” JRMS, Vol. 11, No. 1, 2004, pp. 63-66.
[13]	A. Turlakow, H. W. Yeung, A. S. Salmon, H. A. Macapinlac and S. M. Larson, “Peritoneal Carcinomatosis: Role of (18)F-FDG PET,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, Vol. 44, No. 9, 2003, pp. 1407-1112.
[14]	Y. Bamba, M. Itabashi and S. Kameoka, “Clinical Use of PET/CT in Peritoneal Carcinomatosis from Colorectal Cancer,” Hepatogastroenterology, Vol. 59, No. 117, 2012, pp. 1408-1411.
[15]	S. Smiti and K. V. Rajagopal, “CT Mimics of Peritoneal Carcinomatosis,” Abdominal and Gastrointestinal Radiology, Vol. 20, No. 1, 2010, pp. 58-62.
[16]	R. N. Low, R. M. Barone, C. Lacey, J. S. Sigeti, G. D. Alzate and C. P. Sebrechts, “Peritoneal Tumor: MR Imaging with Dilute Oral Barium and Intravenous Gadolinium-Containing Contrast Agents Compared with Unenhanced MR Imaging and CT,” Radiology, Vol. 204, No. 2, 1997, pp. 513-520.
[17]	U. Tateishi, T. Hasegawa, M. Kusumoto, T. Oyama, H. Ishikawa and N. Moriyama, “Desmoplastic Small Round Cell Tumor: Imaging Findings Associated with Clinicopathologic Features,” Journal of Computer Assisted Tomography, Vol. 26, No. 4, 2002, pp. 579-583. doi:10.1097/00004728-200207000-00018
[18]	M. G. Brizi, L. Natale, R. Manfredi, B. Barbaro, A. Vecchiolo and P. Marano, “Staging of Pancreatic Ductal Adenocarcinoma with Spiral CT and MRI,” Rays, Vol. 26, No. 2, 2001, pp. 151-159.
[19]	J. Esquivel, T. C. Chua, A. Stojadinovic, et al., “Accuracy and Clinical Relevance of Computed Tomography Scan Interpretation of Peritoneal Cancer Index in Colorectal Cancer Peritoneal Carcinomatosis: A Multi-Institutional Study,” Journal of Surgical Oncology, Vol. 102, No. 6, 2010, pp. 565-570. doi:10.1002/jso.21601
[20]	A. M. De Gaetano, M. L. Calcagni, V. Rufini, V. Valenza, A. Giordano and L. Bonomo, “Imaging of Peritoneal Carcinomatosis with FDG PET-CT: Diagnostic Patterns, Case Examples and Pitfalls,” Abdominal Imaging, Vol. 34, No. 3, 2009, pp. 391-402. doi:10.1007/s00261-008-9405-7
[21]	F. Mohamed, T. Cecil, B. Moran and P. Sugarbaker, “A New Standard of Care for the Management of Peritoneal Surface Malignancy,” Current Oncology, Vol. 18, No. 2, 2011, pp. 84-96. doi:10.3747/co.v18i2.663
[22]	E. Cotte, G. Passot, F. Mohamed, D. Vaudoyer, F. N. Gilly and O. Glehen, “Management of Peritoneal Carcinomatosis from Colorectal Cancer: Current State of Practice,” The Cancer Journal, Vol. 15, No. 3, 2009, pp. 243-248. doi:10.1097/PPO.0b013e3181a58d67
[23]	P. H. Sugarbaker, “Cytoreductive Surgery plus Hyperthermic Perioperative Chemotherapy for Selected Patients with Peritoneal Metastases from Colorectal Cancer: A New Standard of Care or an Experimental Approach?” The Lancet Oncology, Vol. 13, No. 8, 2012, pp. e362-e369.
[24]	C. U. Ihemelandu, P. Shen, J. H. Stewart, K. Votanopoulos and E. A. Levine, “Management of Peritoneal CarciNomatosis from Colorectal Cancer,” Seminars in Oncology, Vol. 38, No. 4, 2011, pp. 568-575. doi:10.1053/j.seminoncol.2011.05.011
[25]	P. Piso, M. H. Dahlke, N. Ghali, I. Iesalnieks, M. Loss, F. Popp, et al., “Multimodality Treatment of Per Itoneal Carcinomatosis from Colorectal Cancer: First Results of a New German Centre for Peritoneal Surface Malignancies,” International Journal of Colorectal Disease, Vol. 22, No. 11, 2007, pp. 1295-1300. doi:10.1007/s00384-007-0313-z
[26]	P. H. Sugarbaker, “Management of Peritoneal-Surface Malignancy: The Surgeon’s Role,” Langenbeck’s Archives of Surgery, Vol. 384, No. 6, 1999, pp. 576-587. doi:10.1007/s004230050246